Roivant Sciences Ltd. Common Shares
ROIV Real Time Price USDRecent trades of ROIV by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by ROIV's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Spirocyclic compounds as tryptophan hydroxylase inhibitors Mar. 16, 2021
-
Patent Title: Processes for preparing (r)-1-(5-chloro-[1,1″-biphenyl] -2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1″-biphenyl]-2-yl)-2,2,2-trifluoroethanone Jul. 14, 2020
-
Patent Title: Spirocyclic compounds as tryptophan hydroxylase inhibitors May. 26, 2020
-
Patent Title: Spirocyclic compounds as tryptophan hydroxylase inhibitors Jul. 16, 2019
-
Patent Title: Spirocyclic compounds as tryptophan hydroxylase inhibitors Aug. 14, 2018
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of ROIV in WallStreetBets Daily Discussion
Recent insights relating to ROIV
Recent picks made for ROIV stock on CNBC
ETFs with the largest estimated holdings in ROIV
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view ROIV Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.